Alevca Ocular, a US-based developer of treatments for eye diseases, secured four licences yesterday from Case Western Reserve University’s (CWRU’s) Tech Transfer Office.
The company will initially research inflammations that can result from ocular procedures such as laser eye surgery and cataract removal as well as microbial infections. The company is now also seeking series A funding.
The technology is based on research by Eric Pearlman, a former director of research in CWRU’s Department of Ophthalmology and Visual Sciences who…
